[The hypereosinophilic syndrome: case report].

Abstract

The hypereosinophilic syndrome is a multi-organ disease characterized by large counts of eosinophils in peripheral blood observed during at least six months without any evidence for other known causes of eosinophilia. Idiopathic hypereosinophilia is rare and is always diagnosed by exclusion of other disease. This work describes a man aged 21 years who was hospitalized at the Department of Dermatology because of skin manifestations resembling eczema and urticaria. High eosinophil counts in this patient necessitated a wide array of diagnostic tests. The hypereosinophilic syndrome was diagnosed after more than 12 months of follow-up and exclusion of other causes. Corticosteroids and hydroxycarbamide were administered as first-line therapy. Unfortunately, the patient was unresponsive to steroids. Improvement in peripheral eosinophilia after Glivec therapy correlated with improved clinical status.

• Authors: Katarzyna Mikołajczyk, Ryszard Zaba, Beata Walkowiak, Grzegorz Grzybowski, Włodzimierz Samborski
• Journal: Annales Academiae Medicae Stetinensis (Ann Acad Med Stetin) Vol. 52 Suppl 2 Pg. 65-9 ( 2006) ISSN: 1427-440X [Print] Poland
• Vernacular Title: Zespół hipereozynofilowy--opis przypadku.
• PMID: 17471838 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Benzamides
• Piperazines
• Protein Kinase Inhibitors
• Pyrimidines
• Imatinib Mesylate
• Interferons
• Methylprednisolone
• Hydroxyurea

Topics

• Adult
• Benzamides
• Bone Marrow (pathology)
• Diagnosis, Differential
• Eosinophils (pathology)
• Humans
• Hydroxyurea (therapeutic use)
• Hypereosinophilic Syndrome (diagnosis, drug therapy, pathology)
• Imatinib Mesylate
• Interferons (therapeutic use)
• Lymphatic Diseases (diagnosis, drug therapy, pathology)
• Male
• Methylprednisolone (therapeutic use)
• Piperazines (therapeutic use)
• Protein Kinase Inhibitors
• Pyrimidines (therapeutic use)
• Skin Diseases (diagnosis, drug therapy, pathology)
• Treatment Outcome